JP2009502797A - 血管形成をキュプレドキシンで制御するための組成物および方法 - Google Patents

血管形成をキュプレドキシンで制御するための組成物および方法 Download PDF

Info

Publication number
JP2009502797A
JP2009502797A JP2008522911A JP2008522911A JP2009502797A JP 2009502797 A JP2009502797 A JP 2009502797A JP 2008522911 A JP2008522911 A JP 2008522911A JP 2008522911 A JP2008522911 A JP 2008522911A JP 2009502797 A JP2009502797 A JP 2009502797A
Authority
JP
Japan
Prior art keywords
cupredoxin
peptide
cells
angiogenesis
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008522911A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502797A5 (cg-RX-API-DMAC7.html
Inventor
メータ、ラジェシュワリ
テイラー、ブラッド
亨 山田
ビーティー、クレイグ
グプタ、タパス・ダス
チャクラバーティ、アナンダ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/244,105 external-priority patent/US7691383B2/en
Priority claimed from US11/436,592 external-priority patent/US7381701B2/en
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of JP2009502797A publication Critical patent/JP2009502797A/ja
Publication of JP2009502797A5 publication Critical patent/JP2009502797A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2008522911A 2005-07-19 2006-07-19 血管形成をキュプレドキシンで制御するための組成物および方法 Pending JP2009502797A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70029705P 2005-07-19 2005-07-19
US11/244,105 US7691383B2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof
US76474906P 2006-02-03 2006-02-03
US11/436,592 US7381701B2 (en) 2001-02-15 2006-05-19 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
PCT/US2006/027940 WO2007024368A2 (en) 2005-07-19 2006-07-19 Compositions and methods to control angiogenesis with cupredoxins

Publications (2)

Publication Number Publication Date
JP2009502797A true JP2009502797A (ja) 2009-01-29
JP2009502797A5 JP2009502797A5 (cg-RX-API-DMAC7.html) 2009-09-10

Family

ID=37772089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522911A Pending JP2009502797A (ja) 2005-07-19 2006-07-19 血管形成をキュプレドキシンで制御するための組成物および方法

Country Status (10)

Country Link
EP (1) EP1904081A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009502797A (cg-RX-API-DMAC7.html)
KR (1) KR20080034905A (cg-RX-API-DMAC7.html)
AU (1) AU2006284490A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0615555A2 (cg-RX-API-DMAC7.html)
CA (1) CA2615560A1 (cg-RX-API-DMAC7.html)
IL (1) IL188691A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008000993A (cg-RX-API-DMAC7.html)
NO (1) NO20080829L (cg-RX-API-DMAC7.html)
WO (1) WO2007024368A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158574B2 (en) * 2004-10-07 2012-04-17 Cdg Therapeutics, Inc. Compositions and methods to prevent cancer with cupredoxins
EP2061498A4 (en) * 2006-09-14 2009-11-04 Univ Illinois COMPOSITIONS AND METHOD FOR CANCER PREPARATION WITH CUPREDOXINES
AU2007329375A1 (en) 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and CpG rich DNA

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018662A1 (en) * 2003-08-15 2005-03-03 Board Of Trustees Of The University Of Illinois Use of polypeptides of the cupredoxin family in cancer therapy
WO2006088508A2 (en) * 2004-10-07 2006-08-24 Ananda Chakrabarty Cupredoxin derived transport agents and methods of use thereof
WO2006127514A2 (en) * 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating hiv infection with cupredoxin and cytochrome c
WO2006127477A2 (en) * 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
WO2007018671A2 (en) * 2005-05-20 2007-02-15 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018662A1 (en) * 2003-08-15 2005-03-03 Board Of Trustees Of The University Of Illinois Use of polypeptides of the cupredoxin family in cancer therapy
WO2006088508A2 (en) * 2004-10-07 2006-08-24 Ananda Chakrabarty Cupredoxin derived transport agents and methods of use thereof
WO2006127514A2 (en) * 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating hiv infection with cupredoxin and cytochrome c
WO2006127477A2 (en) * 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
WO2007018671A2 (en) * 2005-05-20 2007-02-15 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins

Also Published As

Publication number Publication date
WO2007024368A3 (en) 2007-10-11
WO2007024368A2 (en) 2007-03-01
IL188691A0 (en) 2008-08-07
AU2006284490A8 (en) 2008-02-28
KR20080034905A (ko) 2008-04-22
NO20080829L (no) 2008-04-02
EP1904081A4 (en) 2008-12-03
EP1904081A2 (en) 2008-04-02
CA2615560A1 (en) 2007-03-01
AU2006284490A1 (en) 2007-03-01
BRPI0615555A2 (pt) 2009-07-14
MX2008000993A (es) 2008-03-19

Similar Documents

Publication Publication Date Title
US8372962B2 (en) Compositions and methods to control angiogenesis with cupredoxins
US10889621B2 (en) Compositions and methods for treating conditions related to ephrin signaling with Cupredoxins
US8232244B2 (en) Compositions and methods to prevent cancer with cupredoxins
US7338766B2 (en) Compositions and methods for treating malaria with cupredoxin and cytochrome
WO2005018662A1 (en) Use of polypeptides of the cupredoxin family in cancer therapy
SG174784A1 (en) Compositions and methods to prevent cancer with cupredoxins
US20160151452A1 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
JP2008539795A (ja) キュプレドキシンを用いたエフリン信号伝達に関する症状を治療するための組成物および方法
KR20110120275A (ko) 큐프레독신으로 암을 예방하기 위한 조성물 및 방법
EP2398486A1 (en) Compositions and methods to prevent and/or treat cancer with pa -card
MX2008000993A (es) Composiciones y metodos para controlar la angiogenesis con cupredoxinas.
CN101272800A (zh) 使用铜氧还蛋白控制血管发生的组合物和方法
JP2008545398A (ja) キュプレドキシンおよびシトクロムcを用いてhiv感染を治療するための組成物および方法
CA2607739A1 (en) Compositions and methods for treating malaria with cupredoxin and cytochrome
ZA200602126B (en) Use of polypeptides of the cupredoxin family in cancer therapy
CN101198351A (zh) 用铜氧还蛋白治疗ephrin信号传导相关性病变的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120515